| [ Summary ] |
It is clear that Helicobacter pylori (H. pylori) eradication inhibits the recurrence of peptic ulcers. H. pylori eradication therapy has achieved a Grade A recommendation, being useful for the treatment of gastric or duodenal ulcers, for the treatment and prevention of H. pylori-associated diseases such as gastric cancer, and for inhibiting the spread of H. pylori infection. It has been reported that onset or aggravation of reflux esophagitis may occur after eradication of H. pylori. The current consensus is that the transient onset or aggravation of reflux esophagitis or GERD symptoms after H. pylori eradication therapy should not interfere with treatment. Instructions concerning lifestyle modification should be given to patients after successful eradication. Recurrence of H. pylori infection after successful eradication has also been reported. Reinfection rates are considered to be approximately 0-2 %/year. |